TG Therapeutics positive Phase 3 ENHANCE results for single 600 mg Day 1 BRIUMVI initiation
TG Therapeutics reports positive Phase 3 ENHANCE results for single 600 mg Day 1 BRIUMVI initiation infusion
- Phase 3 ENHANCE topline data show bioequivalent exposure versus current two-dose BRIUMVI initiation regimen.
- Safety profile for single 600 mg Day 1 infusion comparable to existing two-dose regimen in ENHANCE trial.
- Company plans supplemental BLA filing for single-dose BRIUMVI initiation in the second half of 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.